Physix FrontierPhysix Frontier · News Briefing Card (TMTPost · Sep 21, 2026)
AI Drug Discovery Sees Capital Surge; Insilico Hits $10B Deals
KEY FACTS
- Major developments occurred within a week: Anew Labs secured $290 million in funding, and Novo Nordisk partnered with Anthropic.
- Insilico Medicine disclosed nearly $10 billion in total external partnerships for 2026, far exceeding its revenue from the previous fiscal year.
- Epsivertib, China's first AI-assisted new drug, received approval for market launch, marking AI's formal entry into the drug review process.
- GenScript plans to raise approximately HK$2.3 billion, with 70% of funds dedicated to expanding its AI-driven high-throughput wet lab.
KEY DATA
$290 millionAnew Labs Angel Round Funding
Nearly $10 billionInsilico Medicine 2026 Total Partnerships
Approx. HK$2.327 billionGenScript Net Placement Proceeds
98.4 mLRentosertib Phase II FVC Improvement
PHYSIX OBSERVATION
AI drug discovery is shifting from 'model showmanship' to 'systematic output,' with the core bottleneck moving from algorithms and compute to the scalability and standardization of wet-lab validation. The industry's competitive focus has become building a closed loop of 'dry-wet-data'; whoever can provide reproducible experimental feedback at low cost and high speed will hold pricing power. Companies holding only models or pipelines face value re-evaluation, while platform service providers with infrastructure attributes and pharma companies with real clinical data will emerge as the new winners.
Source: TMTPost report